Definition of the intrinsic molecular controls that regulate angiogenic and vasculogenic blood vessel growth promises to provide targets for therapy of solid tumors, diabetic retinopathy, arthritis, skin and other diseases. Developmental assembly, remodeling and maintenance of microvascular integrity are dynamic processes regulated by endothelial responses to local environmental cues, transduced through surface receptors. One of the properties fundamental to endothelium in mature vessels is cell context dependent constraints over proliferation. We have advanced the hypothesis that an endothelial receptor tyrosine phosphatase, ECRTP/CD148, transduces cell growth arrest signals on juxtacrine contact with a counter-receptor. A monoclonal antibody, ECRTP.ab1, that specifically binds ECRTP/CD148 ectodomain sequences localizes its expression to endothelium of arteries and capillaries in kidney, and other tissues. Endothelial progenitor cells express ECRTP/CD148 prior to their incorporation into developing glomerular capillaries of kidney, and ECRTP/CD148 accumulates at inter-endothelial points of contact. Bivalent forms of ECRTP.ab1 block cultured endothelial cell proliferation and migration, inhibit angiogenesis in a mouse corneal assay, and promote dephosphorylation of intracellular tyrosine phosphoproteins. Expression of ECRTP/CD148 in deficient cell lines confers antibody-induced growth inhibition that is dependent upon intrinsic tyrosine phosphatase activity. The current proposal describes plans to: 1) define a functional counter-receptor to CD148, 2) to identify intracellular substrates of ECRTP/CD148 and their role in endothelial growth arrest, and 3) to define ECRTP/CD148 function during vascular development. Homologous recombinant ES lines and mice will define function of ECRTP/CD148 in developmental vascular assembly. These studies will extend definition of molecular controls regulating angiogenesis, and will define new molecular targets for anti-angiogenic therapies.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Pathology A Study Section (PTHA)
Program Officer
Scherbenske, M James
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Takahashi, Keiko; Kim, Rachel; Lauhan, Colette et al. (2017) Expression of receptor-type protein tyrosine phosphatase in developing and adult renal vasculature. PLoS One 12:e0177192
Takahashi, Keiko; Matafonov, Anton; Sumarriva, Katherine et al. (2014) CD148 tyrosine phosphatase promotes cadherin cell adhesion. PLoS One 9:e112753
Takahashi, Keiko; Mernaugh, Raymond L; Friedman, David B et al. (2012) Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase. Proc Natl Acad Sci U S A 109:1985-90
Qu, Xianghu; Tompkins, Kevin; Batts, Lorene E et al. (2010) Abnormal embryonic lymphatic vessel development in Tie1 hypomorphic mice. Development 137:1285-95
Tsuboi, Nobuo; Utsunomiya, Tadahiko; Roberts, Richard L et al. (2008) The tyrosine phosphatase CD148 interacts with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 413:193-200
Takahashi, Takamune; Takahashi, Keiko; Mernaugh, Raymond L et al. (2006) A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis. Blood 108:1234-42
Takahashi, Takamune; Takahashi, Keiko; St John, Patricia L et al. (2003) A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development. Mol Cell Biol 23:1817-31
Du, Jianguo; Luan, Jing; Liu, Hua et al. (2002) Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. J Leukoc Biol 71:141-53
Daniel, T O; Abrahamson, D (2000) Endothelial signal integration in vascular assembly. Annu Rev Physiol 62:649-71
Addison, C L; Daniel, T O; Burdick, M D et al. (2000) The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 165:5269-77

Showing the most recent 10 out of 30 publications